Tag: licensing
-
Gastric Model Lands Funding for Expanded Applications
An artificial digestive system developed at the Institute of Food Research in Norwich, U.K. for lab tests of physical and biochemical processes in the human stomach and intestines, secured more than £900,000 ($US 1.4 million) for research on new models of nutritional quality and health benefits. The two-year grant is provided to the Institute of…
-
Merck, Samsung to Collaborate on Biosimilars
The pharmaceutical company Merck & Co. in New Jersey and Samsung Bioepis Co. in Seoul, South Korea agreed on a deal for licensing and taking to market non-branded biologic therapies called biosimilars. While the companies released an outline of the financial arrangements, the dollar amount of the agreement was not disclosed. Biosimilars are treatments and…
-
Biotechs to Partner on Cancer Therapy, Drug Production
The biotechnology companies iBio Inc. in Newark, Delaware and Caliber Biotherapeutics in Bryan, Texas agreed to combine their plant-based genomic drug discovery and development technologies to produce new therapeutics, beginning with a cancer drug. Financial aspects of the deal were not disclosed. iBio’s platform, called iBio Launch, uses plant biology to harness gene expression for…
-
Roche, Biotech to Partner on Growth Hormone Disorders
The Swiss pharmaceutical company Roche will license a compound developed by biotechnology company Chiasma Inc., based in New York and Jerusalem, to treat the hormonal disease acromegaly and neuroendocrine tumors. The deal has a total potential value to Chiasma of $595 million. Chiasma develops drugs for oral administration previously available in injection form. The company’s…
-
Company, University to Develop 3D Models for Cancer Research
Organovo Holdings Inc. in San Diego, with Oregon Health and Science University in Portland, will develop three dimensional human tissue models to replicate cancer disease for lab testing of potential therapies. The partnership, for which financial terms were not disclosed, will apply Organovo’s 3D printing technology that builds tissue models for testing cancer treatments more…
-
Sanford-Burnham, Intrexon to Partner on Stem Cell Technology
Intrexon Corporation in Germantown, Maryland and Sanford-Burnham Medical Research Institute in La Jolla, California will collaborate on research with induced pluripotent stem cells. The deal gives Sanford-Burnham access to Intrexon’s latest stem cell processing technology in exchange for commercial and intellectual property rights to technological advances under the agreement. Financial aspects of the deal were…
-
University, Companies Partner on Air Cleaning Technology
A chemistry professor at University of Copenhagen in Denmark is working with a Danish entrepreneur and waste processor to test a process for cleaning polluting particles from industrial emissions. Environmental chemist Matthew Johnson (pictured right) and the university have also patented the process he devised, which is based on on the natural ability of the…
-
Clinical Trial Underway for Cancer Stem Cell Therapy
OncoMed Pharmaceuticals Inc., a biotechnology company in Redwood City, California, began dosing patients enrolled in a clinical trial of its therapy addressing cancer stem cells. The phase 1 trial is testing OMP-52M51, a monoclonal antibody — a type of engineered antibody molecule — designed for patients with hematologic cancers, in this case lymphoid malignancies. Cancer…
-
Wake Forest Health Expands Commercialization Program
Wake Forest Baptist Medical Center in Winston-Salem, North Carolina started a new division to encourage development of new products and services from its research. Wake Forest Innovations, as the division is called, is expected to generate new revenue streams for the medical center by growing and managing new business partnerships. Wake Forest Innovations has a…
-
MD Anderson, GlaxoSmithKline Partner on Cancer Immunotherapy
MD Anderson Cancer Center in Houston, part of the University of Texas, and the global pharmaceutical company GlaxoSmithKline will jointly conduct research leading to new therapeutic antibodies that help the immune system fight cancer. The agreement over its full lifetime could earn MD Anderson as much as $335 million. The agreement gives GlaxoSmithKline exclusive worldwide…